skip navigation
°í·Á´ëÇб³ ÀÇ·á¿ø
âÁ¶ÀûÀÎ Çõ½Å°ú ²÷ÀÓ¾ø´Â µµÀüÀ¸·Î ±¹¹Î¿¡°Ô ½Å·Ú¹Þ´Â ÀÇ·á¿ø¾Æ·¡ °Ë»öÀ» ÅëÇØ Á¤È®ÇÏ°í ºü¸£°Ô ÀÇ·áÁøÀ» °Ë»öÇÒ ¼ö ÀÖ½À´Ï´Ù.
Áø·á°ú¸¦ ¾È³»ÇØ µå¸³´Ï´Ù. Ŭ¸¯ ½Ã ÇØ´ç Áø·á°úÀÇ ÀÚ¼¼ÇÑ »çÇ×À» º¸½Ç ¼ö ÀÖ½À´Ï´Ù.
±¹¹® ³í¹®¸í | |
---|---|
¿µ¹® ³í¹®¸í | A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteers. Expert Opinion on Investigational Drugs. 2017;26(5):619-624 |
Á¾·ù | SCI |
Ã¥ÀÓÀúÀÚ | |
Á¦1ÀúÀÚ | |
ÀúÀÚ | |
¹ßÇàÁ¤º¸ |